ema semaglutide naion june 2025 The use of medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION) GLP-1 Drug Can Cause Rare,

This material is supplied exclusively for research use and is not intended for human or animal use

Implementing nutritional therapy for hypoglycemia individuals presents challenges

From a theoretical pharmacological standpoint, combining a peptide with putative lipolytic activity (AOD 9604) with a potent triple incretin receptor agonist (retatrutide) could potentially amplify metabolic effects but this is speculative and raises the possibility of compounding adverse effects with no safety data to guide dosing or monitoring

The results indicated a significant association between serum uric acid levels and four health outcomes: diabetic macrovascular disease, arterial stiffness, renal events, and gout

The effects were long-lasting and still present at early adulthood